潘登 - 清华大学

个人简介

潘登博士从事肿瘤免疫、肿瘤免疫治疗耐受机制以及肿瘤细胞信号转导研究，在美国MD Anderson Cancer Center获得博士学位，在哈佛医学院/丹娜法伯癌症研究所（Dana Farber Cancer Institute/Harvard Medical School）从事博士后研究，并于2019年全职任教于清华大学医学院。潘登博士围绕肿瘤免疫治疗的耐受机制展开研究：采用全基因组CRISPR/Cas9筛选和功能基因组并结合计算生物学的方法，发现了多个调控肿瘤细胞对免疫治疗耐受的相关基因以及信号通路，为肿瘤免疫治疗提供新的靶点，相关研究发表在Science以及Nature Medicine等杂志上。近年来，获得多项学术奖励和基金，包括美国Cancer Research Institute Fellowship，中组部千人计划青年项目，清华-拜耳研究员等。 Resume 2019-Present, Principle Investigator, School of Medicine, Center for Life Sciences, Tsinghua University, Beijing, China 2016-2019, Research Fellow, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA 2010-2016, Ph.D. in Cancer Biology, UT MD Anderson Cancer Center, Houston, TX 2005-2010, B.S. in Medicine, Southern Medical University, Guangzhou, China

研究领域

1. Targeting Immune Evasion Mechanisms in Cancer Through cutting-edge functional genomic approaches and by establishing various in vitro and in vivo screening assays, we investigate the pathways employed by tumor cells to thwart elimination by different types of immune cells, such as CD8+ T cells, NK cells, and macrophages.By unraveling these intricate pathways, our goal is to gain a comprehensive understanding of immune evasion mechanisms, paving the way for the development of novel and effective strategies in cancer immunotherapy. 2. Identification of key functional interactions in the tumor microenvironment Tumor microenvironment (TME) is highly immune suppressive. Targeting the interactions of key negative regulators of anti-tumor immunity (e.g., PD-1/PD-L1) could effectively boost the anti-tumor immune response. Through the integration of functional genetic perturbation and single-cell technologies, we aim to map the key immune regulatory and druggable interactions in the tumor microenvironment. By deciphering these crucial interactions, the ultima

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, Yu X, Xiong K, Luo C, Zhu J, Wang F#, Zeng Z#, Pan D#. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNFa. Cell Metabolism, In Press. doi: 10.1016/j.cmet.2023.07.001 (# denotes corresponding authors) https://pubmed.ncbi.nlm.nih.gov/37506695/ Ito Y*, Pan D*, Zhang W, Zhang X, Juan TY, Pyrdol JW, Kyrysyuk O, Doench JG, Liu XS, Wucherpfennig KW. Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines. Cancer Discovery. 2023 May 4;13(5):1186-1209. doi: 10.1158/2159-8290.CD-22-1125. (* Denotes equal contribution) Rongqing Pan, Jeremy Ryan, Deng Pan, Kai W Wucherpfennig, Anthony Letai. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell? 2022 Apr 28;185(9):1521-1538.e18. doi: 10.1016/j.cell.2022.03.030. Epub 2022 Apr 20. Meng J, Jiang YZ, Zhao S, Tao Y, Zhang T, Wang X, Zhang Y, Sun K, Yuan M, Chen J, Wei Y, Lan X, Chen M, David CJ, Chang Z, Guo X, Pan D, Chen M, Shao ZM, Kang Y, Zheng H. Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell Rep. 2022 Mar 8; 38(10):110492 Shi S, Gu S, Han T, Zhang W, Huang L, Li Z, Pan D, Fu J, Ge J, Brown M, Zhang P, Jiang P, Wucherpfennig KW, Liu XS. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. Clin Cancer Res. 2020 Nov 15;26(22):5990-6002. Ferrari de Andrade L, Kumar S, Luoma AM, Ito Y, Alves da Silva PH, Pan D, Pyrdol JW, Yoon CH, Wucherpfennig KW. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells Cancer Immunol Res. 2020 Jun;8(6):769-780. De Andrade LF, Lu Y, Luoma A, Ito Y, Pan D, Pyrdol JW, Yoon CH, Yuan GC, Wucherpfennig KW.Discovery of specialized NK cell populations infiltrating human melanoma metastasis. JCI Insight. 2019 Dec 5;4(23):e133103. Pan D*, Kobayashi A*, Jiang P*, Andrade LF, Tay RE, Luoma A, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan G, Doench J, Brown M, Liu XL, and Wucherpfennig KW. A Major Chromatin Regulator Determines Resistance of Tumor cells to T cell Mediated Killing. Science, 2018 Jan 4; pii:eaao1710 doi: 10.1126/science.aao1710. (* Denotes equal contribution) (Highlighted paper for postdoctoral work) Jiang P*, Gu S*, Pan D*, Fu J, Li Z, Bu X, Li B, Liu JS, Freeman G, Brown M, Wucherpfennig KW and Liu XL. Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018 Oct;24(10):1550-1558. (* Denotes equal contribution) (Highlighted paper for postdoctoral work) Andrade LF, Tay RE, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi S, Dranoff G and Wucherpfennig KW. Antibody-Mediated Blockade of MICA/B Shedding Promotes NK Cell-Driven Tumor Immunity. Science 2018, Mar 30; Vol 359, Issue 6383, pp. 1537-1542) DOI: 10.1126/science.aao0505 Zhang S, Pan D, Jia XM, Lin X and Zhao X. The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-kB activation and cell survival. Protein Cell. 2017 Nov; 8(11):856-860. Wang A, Ding X, Demarque M, Liu X, Pan D, Xin H, Zhong B, Wang X, Dejean A, Jin W and Dong C. Ubc9 Is Required for Positive Selection and Late-Stage Maturation of Thymocytes. J Immunol. 2017 May 1; 198(9): 3461-3470. Pan D, Jiang C, Ma Z, Blonska M, You MJ and Lin X. The role of MALT1 in EGFR induced NF-kappaB activation and EGFR associated lung cancer progression. Oncogene. 2016 Feb 18; 35(7):919-28. Pan D*, Zhu Y*, Zhou Z, Wang T, You H, Jiang C and Lin X. CARMA3-BCL10-MALT1 -mediated NF-kB activation contributes to HRE2-assocaited tumor malignancy in breast cancer. Mol Cancer Res. 2016 Jan ;14(1):93-102. (* denotes equal contribution) Wang T, Pan D, Zhou Z, You Y, Jiang C, Zhao X and Lin X. Dectin-3 Deficiency Promotes Colitis Development due to Impaired Antifungal Innate Immune Responses in the Gut. PLoS Pathog; 2016 Jun 9;12(6): e1005662. Pan D and Lin X. EGFR-activated NF-kappaB Signaling and Its Role in EGFR-associated Tumors. Cancer J. 2013 Nov-Dec;19(6):461-7. Wang A, Pan D, Lee Y, Gustavo M, Feng XF, and Dong C. Cutting Edge: Smad2 and Smad4 regulate TGFbeta-mediated Il9 gene expression via EZH2 displacement. J Immunol. 2013 Nov 15; 191(10):4908-12. Pan D, Hu J, Ma Q, Pan W and Li M. Diversity and prevalence of the C-terminal region of Plasmodium falciparum Merozoite Surface Protein 1 in China. Acta Trop. 2010 Dec; 116(3): 200-5.